Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization.
K. Paul Friedman, M. Gagne, L. Loo, P. Karamertzanis, T. Netzeva, T. Sobański, Jill A. Franzosa, A. Richard, Ryan R. Lougee, A. Gissi, J. J. Lee, M. Angrish, J. Dorne, S. Foster, K. Raffaele, T. Bahadori, M. Gwinn, J. Lambert, M. Whelan, M. Rasenberg, T. Barton-Maclaren, Russell S. Thomas
Toxicological Sciences